US20080255048A1 - Pharmaceutical Composition - Google Patents

Pharmaceutical Composition Download PDF

Info

Publication number
US20080255048A1
US20080255048A1 US12/093,383 US9338306A US2008255048A1 US 20080255048 A1 US20080255048 A1 US 20080255048A1 US 9338306 A US9338306 A US 9338306A US 2008255048 A1 US2008255048 A1 US 2008255048A1
Authority
US
United States
Prior art keywords
composition
pharmaceutical composition
calcitonin
dissolution
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/093,383
Other languages
English (en)
Inventor
Moise Azria
Simon David Bateman
Anasuya Ashok Ghosh
Shoufeng Li
Alan Edward Royce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/093,383 priority Critical patent/US20080255048A1/en
Publication of US20080255048A1 publication Critical patent/US20080255048A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Definitions

  • the present invention relates to a novel pharmaceutical composition for the oral delivery of pharmaceutical compounds, in particular poly(amino acids) including peptides or, alternatively, peptidomimetics.
  • the present invention relates in an embodiment to a novel oral pharmaceutical composition containing a poly(amino acid), for the treatment of a disorder caused by abnormal bone resorption and/or to the treatment of an arthritic condition and to other subject matter.
  • Poly(amino acids) which have been used or proposed to be used for pharmaceutical or veterinary purposes include, but are not limited to the following, including synthetic, natural or recombinant sources thereof: polypeptide hormones such as calcitonins, e.g. salmon calcitonin, growth hormone, including human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, and porcine growth hormones; growth hormone-releasing hormones and pituitary thyroid hormone.
  • polypeptide hormones such as calcitonins, e.g. salmon calcitonin
  • growth hormone including human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, and porcine growth hormones
  • growth hormone-releasing hormones e.g., calcitonins, e.g. salmon calcitonin
  • hGH human growth hormones
  • rhGH recombinant human growth hormones
  • bovine growth hormones
  • the parathyroid hormone or PTH can be the full length, 84 amino acid form of parathyroid hormone, e.g. the human form, hPTH (1-84), or any polypeptide, protein, protein fragment, or modified fragment, i.e. PTH-related peptides and PTH analogs, capable of mimicking the activity of hPTH (1-84) in controlling calcium and phosphate metabolism to build bone in the human body.
  • the PTH fragments will generally incorporate at least the first 28 N-terminal residue and include by way of example PTH (1-28), PTH (1-31), PTH (1-34), PTH (1-37), PTH (1-38) and PTH (1-41) and analogues thereof, e.g. PTS893.
  • the PTH can be a single PTH or any combination of two or more PTHs.
  • the preferred PTH fragment is PTH (1-34).
  • parathyroid hormones are commercially available or can be obtained recombinantly, by peptide synthesis, or by extraction from human fluid by methods well established in the art.
  • the amount of PTH to be administered is generally an amount effective to stimulate new bone formation i.e. a therapeutically effective amount. This amount will necessarily vary with the age, size, sex and condition of the subject to be treated, the nature and severity of the disorder to be treated and the like. However, the unit amount can be less than the described dosage when a plurality of the compositions are to be administered, i.e., the total effective amount can be administered in cumulative dosage units. The unit amount of PTH can also be more than the effective amount when the composition provides sustained release of the pharmacologically active agent.
  • the total amount of PTH to be used can be determined by methods known to those skilled in the art. However, in general, satisfactory results will be obtained systemically at daily dosages of from about 0.001 ⁇ g/kg to about 10 mg/kg animal body weight, preferably 1 ⁇ g/kg to about 6 ⁇ g/kg body weight.
  • the preferred pharmacologically active agent is a pharmacologically active peptide, particularly calcitonin.
  • a known class of pharmacologically active agents, calcitonins have varying pharmaceutical utility and are commonly employed in the treatment of e.g. Paget's disease, hypercalcemia and postmenopausal osteoporosis.
  • Calcitonins e.g. salmon, (Asul-7)-eel or human calcitonin, are compounds which are long-chain polypeptide hormones secreted by the parafollicular cells of the thyroid gland in mammals and by the ultimobranchial gland of birds and fish.
  • calcitonins including salmon, pig and eel calcitonin are commercially available and commonly employed for the treatment of e.g. Paget's disease, hypercalcemia of malignancy and osteoporosis.
  • the calcitonin can be any calcitonin, including natural, synthetic or recombinant sources thereof, as well as calcitonin derivatives such as 1,7-Asu-eel calcitonin.
  • the compositions can comprise a single calcitonin or any combination of two or more calcitonins.
  • the preferred calcitonin is synthetic salmon calcitonin.
  • the calcitonins are commercially available or may be synthesized by known methods.
  • the amount of pharmacologically active agent is generally an amount effective to accomplish the intended purpose, e.g. a therapeutically effective amount.
  • the unit amount can be less than the described dosage when a plurality of the compositions are to be administered, i.e., the total effective amount can be administered in cumulative dosage units.
  • the unit amount of active agent can also be more than the effective amount when the composition provides sustained release of the pharmacologically active agent.
  • the total amount of active agent to be used can be determined by methods known to those skilled in the art. However, because the compositions may deliver the active agent more efficiently than prior compositions, less amounts of active agent than those used in prior dosage unit forms or delivery systems can be administered to a subject while still achieving the same blood levels and/or therapeutic effects.
  • calcitonin to be administered will, of course, vary depending upon, for example, the amount of calcitonin to be administered and the severity of the condition being treated. However, in general, satisfactory results will be obtained through systemic intranasal or injectable administration at daily dosages of from about 0.5 ⁇ g/kg to about 10 ⁇ g/kg animal body weight, preferably 1 ⁇ g/kg to about 6 ⁇ g/kg body weight.
  • hGH Human Growth Hormone
  • somatotropic hormone or somatotropin
  • somatotropin is a polypeptide hormone secreted by the anterior lobe of the pituitary gland that promotes growth of the body, especially by stimulating release of somatomedin, and that influences the metabolism of proteins, carbohydrates, and lipids.
  • hGH definition may also be any of various natural or synthetic substances that regulate the growth of animals or plants, such as pituitary growth hormone in vertebrates and auxins in plants.
  • a first class of disorders fall in the class relating to disorders caused by bone resorption. Examples of such disorders are osteoporosis, osteolyisis and Paget's disease.
  • arthritic conditions In a second class of disorders are arthritic conditions.
  • An example of such disorders is osteoarthritis.
  • the present invention therefore provides a pharmaceutical composition that enables the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins, e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect.
  • poly (amino acids) such as peptides, peptidomimetics and proteins, e.g. hormones
  • the present invention further provides an oral pharmaceutical composition
  • a poly (amino acid) active ingredient e.g. a peptide or protein, in which the disintegration time of the pharmaceutical composition and/or the rate of dissolution are rapid such that the active ingredient is able to attain a therapeutic effect.
  • the present invention provides pharmaceutical compositions comprising a peptide or protein active ingredient in which the disintegration time of the pharmaceutical composition, e.g. tablet, is up to ten minutes.
  • the present invention also provides a pharmaceutical composition, e.g. tablet or capsule that has a dissolution time of up to thirty minutes, for example up to twenty minutes, usually up to ten minutes.
  • a pharmaceutical composition e.g. tablet or capsule that has a dissolution time of up to thirty minutes, for example up to twenty minutes, usually up to ten minutes.
  • the present invention provides pharmaceutical compositions comprising a calcitonin as the active ingredient together with the delivery agent 5-CNAC, where the pharmaceutical composition is manufactured in such a way so as to provide improved oral bioavailability, e.g. satisfactory or optimal oral bioavailability for the calcitonin active ingredient.
  • Bioavailability is to be understood within the scope of the present invention the percent of dose entering the systemic circulation after administration of a given dosage form. More explicitly, the ratio of the amount of drug “absorbed” from a test formulation to the amount “absorbed” after administration of a standard formulation. Frequently, the “standard formulation” used in assessing bioavailability is the aqueous solution of the drug, given intravenously.
  • the amount of drug absorbed is taken as a measure of the ability of the formulation to deliver drug to the sites of drug action; which depends on the disintegration and dissolution properties of the dosage form, and the rate of biotransformation relative to rate of absorption.
  • Dosage forms containing identical amounts of active drug may differ markedly in their abilities to make drug available, and therefore, in their abilities to permit the drug to manifest it's expected pharmacodynamic and therapeutic properties.
  • the present invention thus further provides a pharmaceutical composition capable of delivering a peptide or protein via oral administration without the need for an enteric coating or a peptidase inhibitor.
  • the compositions of the invention are free of enteric coating or peptidase inhibitors, or both.
  • the calcitonin-containing pharmaceutical compositions of the present invention may be used to treat disorders relating to abnormal bone resorption or to treat arthritic conditions, as described herein.
  • the invention relates to an oral pharmaceutical composition in the solid phase comprising:
  • composition according to the invention has a disintegration time of no more than 2 minutes.
  • the composition according to the invention additionally comprises a disintegrant, particularly a disintegrant selected from any superdisintegrant, such as a crospovidone or a povidone and/or another agent that decreases disintegration time, for example by effervescent and/or other means.
  • a disintegrant particularly a disintegrant selected from any superdisintegrant, such as a crospovidone or a povidone and/or another agent that decreases disintegration time, for example by effervescent and/or other means.
  • a pharmaceutical composition having a dissolution time of >80% at no more than 20 minutes in gastric media.
  • the invention further relates to a pharmaceutical compositions which is in form of a tablet, particularly a compressed tablet, wherein the tablet has a hardness of between 3 Kp and 20 Kp, particularly of between 5 Kp and 15 Kp, more particularly of between 5 Kp and 7 Kp.
  • the composition according to the invention comprises a polypeptide hormone, particularly a calcitonin, more particularly a salmon calcitonin.
  • the calcitonin is present in a therapeutically effective amount in free or salt form that provides a peak plasma concentration (C max ) of no less than 400 pg/mL, particularly no less than 800 pg/mL, more particularly no less than 1000 pg/mL, and/or a reduction in plasma calcium level of >20% in 6 hours in primate animal models, in particular monkeys.
  • C max peak plasma concentration
  • a composition comprising a therapeutically effective amount of a calcitonin in free or salt form in a dosage range of between 0.15 mg and 2.5 mg, particularly of between 0.15 mg and 0.4 mg.
  • composition according to the invention may further comprise the delivery agent 5-CNAC and/or crospovidone and/or povidone as a disintegrant. Additionally the composition may comprise one or more of a thickening agent, a stabilizer and a dry binder.
  • the pharmaceutical composition is provided in form of a tablet, which has a weight of 500 mg.
  • composition comprising:
  • the invention relates to the use of the pharmaceutical composition according to the invention and as described herein before for the manufacture of a medicament for the treatment of a disease caused by abnormal bone resorption such as, for example, osteoporosis, an arthritic disease, or osteoarthritis.
  • a disease caused by abnormal bone resorption such as, for example, osteoporosis, an arthritic disease, or osteoarthritis.
  • the invention further relates to a method of determining the absorption properties of a composition according to the invention and as described herein before comprising
  • the invention relates to a method of pre-determining peak plasma concentration (C max ) of an active ingredient in a patient to be treated with an oral pharmaceutical composition comprising said active ingredient, particularly calcitonin, more particularly salmon calcitonin, and a delivery agent which method comprises adjusting the disintegration time of the pharmaceutical composition and/or the dissolution time of the active ingredient such as to provide a favorable microenvironment in the gastro intestinal tract for the dissolution of the active ingredient in the intestine in order to optimize absorption of the active ingredient and to achieve a therapeutically effective peak plasma concentration of the active ingredient in the blood plasma, in particular a peak plasma concentration of no less than 400 pg/mL.
  • C max peak plasma concentration
  • the favorable microenvironment in the gastro intestinal tract for the dissolution of the active ingredient in the intestine may be provided by the addition of 5-CNAC to the composition.
  • a method of pre-determining peak plasma concentration (C max ) of an active ingredient in a patient to be treated with an oral pharmaceutical composition wherein the oral pharmaceutical composition is provided in form of a tablet and the disintegration time is adjusted by adapting the hardness of the tablet, particularly a tablet the hardness of which is in a range of between 3 Kp and 20 Kp and/or wherein the disintegration time is less than 10 min, particularly less than 1 min.
  • the invention relates to the use, to manufacture an oral pharmaceutical composition having a disintegration time and/or a dissolution time of not more than 10 minutes, of:
  • 5-CNAC may be used to provide a favorable microenvironment in the gastro intestinal tract for the dissolution of salmon calcitonin.
  • the present invention provides an oral pharmaceutical composition
  • a poly (amino acid) active ingredient e.g. a peptide or a protein, in which the disintegration time of the pharmaceutical composition is such that the active ingredient is able to attain an adequate therapeutic effect.
  • the present invention further provides an oral pharmaceutical composition
  • a poly (amino acid) active ingredient e.g. a peptide or a protein, in which the rate of dissolution of the pharmaceutical composition is such that the active ingredient is able to attain an adequate therapeutic effect.
  • the present invention further provides an oral pharmaceutical composition
  • a poly (amino acid) active ingredient e.g. a peptide or a protein, in which both the disintegration time and the rate of dissolution of the pharmaceutical composition are such that the active ingredient is able to attain an adequate therapeutic effect.
  • compositions of the present invention may not require as much active ingredient to be present compared to compositions without the properties of the compositions described herein. This will, of course, not only have the benefit of reducing production costs of the resulting medicinal products but also reduced the risk of forming unwanted, or even toxic, metabolites of the active ingredient in the patient.
  • compositions of the present invention may provide a method whereby the therapeutic level of an active ingredient, e.g. the plasma concentration of an active ingredient, may be controlled.
  • the desired plasma concentration in any given time may be predetermined by choosing a particular composition with a particular disintegration time and/or a particular dissolution time.
  • the present invention also includes a library of compositions, each having different disintegration and/or dissolution properties by ways as herein described.
  • One particular library of compositions comprises a library of tablets, each having different a hardness, e.g. from 3 Kp to 20 Kp, particularly from 5 Kp to 20 Kp, more particularly from 5 Kp to 15 Kp, but especially from 5 Kp to 7 Kp.
  • each tablet of each hardness may also differ in the amount of active ingredient, carrier, diluent, lubricant, glidant or disintegrant, for example.
  • the current invention also includes a library of compositions, where the absence of lubricant may contribute to a faster onset of disintegration and dissolution.
  • the present invention provides an oral pharmaceutical composition that has one or both of a dissolution time or disintegration time of up to ten minutes.
  • the present invention provides compositions for which the degree of dissolution is between 20% and 100% using USP II paddle method in 0.1N HCl and 0.01% Tween-80 dissolution media over a prescribed period of time.
  • compositions of the invention have a degree of dissolution of between 20% and 100%, e.g. 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 100% over a period of 0 to 60 minutes, for example 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55 and 60 minutes.
  • the dissolution times and degree of dissolution correlate to compositions having a disintegration time of less than ten minutes.
  • the composition has a disintegration time of no more than 10 minutes and a dissolution of >80% at no more than 20 minutes, particularly a disintegration time of no more than 6 minutes and a dissolution of >90% at no more than 20 minutes, particularly in gastric media.
  • the dissolution time of a compound may directly effect the plasma concentration of an active ingredient at any given time.
  • the present invention therefore includes a pharmaceutical composition in the solid phase comprising:
  • the present invention includes:
  • compositions for the oral delivery of poly(amino acids) comprising (i) a poly(amino acid) (ii) a delivery agent (iii) a diluent wherein the composition has a dissolution time of no more than 10 minutes.
  • the present invention also includes:
  • the solid composition may be in the form of a tablet.
  • the tablet may be compressed in a manner as described herein.
  • the poly(amino acid) may be any poly(amino-acid) drug, e.g. comprising a protein or protein fragment. It may be any poly (amino acid) described above under the heading “Background to the Invention”.
  • the poly(amino acid) is a hormone, for example a polypeptide hormone such as a calcitonin, e.g. salmon calcitonin, a growth hormone, including human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, and porcine growth hormones; growth hormone-releasing hormones and a pituitary thyroid hormone, for example.
  • the poly(amino acid) is preferably a pharmaceutically active ingredient.
  • a particularly preferred class of pharmaceutical compositions comprises salmon calcitonin as active ingredient.
  • the poly(amino-acid) may be in free or salt form.
  • the delivery agent may be any delivery agent suitable for delivering poly(amino acid)s by oral administration.
  • the delivery agents useful in the formulation e.g. the oral formulation, are any agents useful for delivering the particular pharmacologically active agent.
  • Suitable delivery agents are any one of the modified amino acids disclosed in aforementioned U.S. Pat. No. 5,866,536 or any one of the modified amino acids described in the aforementioned U.S. Pat. No. 5,773,647 or any combination thereof.
  • the contents of the aforementioned U.S. Pat. Nos. 5,773,647 and 5,866,536 are hereby incorporated by reference in their entirety.
  • the delivery agent can be the disodium salt of any of the aforementioned modified amino acids as well as ethanol solvates and hydrates thereof.
  • Suitable compounds include compounds of the following formula I
  • the delivery agent can be the disodium salt of any of the aforementioned modified amino acids as well as ethanol solvates and hydrates thereof.
  • the disodium salt may be prepared from the ethanol solvate by evaporating or drying the ethanol solvate by methods known in the art to form the anhydrous disodium salt. Drying is generally carried out at a temperature of from about 80 to about 120° C., preferably from about 85 to about 90° C., and most preferably at about 85° C. The drying step is generally performed at a pressure of 26′′Hg or greater.
  • the anhydrous disodium salt generally contains less than about 5% by weight of ethanol and preferably less than about 2% by weight of ethanol, based on 100% total weight of anhydrous disodium salt.
  • the disodium salt of the delivery agent can also be prepared by making a slurry of the delivery agent in water and adding two molar equivalents of aqueous sodium hydroxide, sodium alkoxide or the like.
  • Suitable sodium alkoxide include, but are not limited to, sodium methoxide, sodium ethoxide, and combinations thereof.
  • a still further method of preparing the disodium salt is by reacting the delivery agent with one molar equivalent of sodium hydroxide to yield the disodium salt.
  • the disodium salt can be isolated as a solid by concentrating the solution containing the disodium salt to a thick paste by vacuum distillation. This paste may be dried in a vacuum oven to obtain the disodium salt of the delivery agent as a solid.
  • the solid can also be isolated by spray drying an aqueous solution of the disodium salt.
  • the delivery agents may be prepared by methods known in the art, e.g., as mentioned above, by methods described in U.S. Pat. Nos.
  • the ethanol solvates include, but are not limited to, a molecular or ionic complex of molecules or ions of ethanol solvent with molecules or ions of the disodium salt of the delivery agent.
  • the ethanol solvate contains about one ethanol molecule or ion for every molecule of disodium salt of the delivery agent.
  • the ethanol solvate of the disodium salt of the delivery agent can be prepared by dissolving the delivery agent in ethanol.
  • each gram of delivery agent is dissolved in from about 1 to about 50 mL of ethanol and generally, from about 2 to about 10 mL of ethanol.
  • a sodium containing salt such as a monosodium containing salt
  • a monosodium containing salt relative to delivery agent, i.e. for every mole of delivery agent there is more than one mole of sodium cations, yielding the ethanol solvate.
  • Suitable monosodium salts include, but are not limited to, sodium hydroxide; sodium alkoxide, such as sodium methoxide and sodium ethoxide; and any combination of the foregoing.
  • the reaction is performed at or below the reflux temperature of the mixture, such as at ambient temperature.
  • the ethanol solvate is then recovered by methods known is the art, such as, concentration of the resulting slurry at atmospheric distillation, cooling the concentrated slurry and filtering the solid. The recovered solid can then be vacuum dried to obtain the ethanol solvate.
  • the hydrates of the disodium salts of the delivery agents may be prepared by drying the ethanol solvate to from an anhydrous disodium salt, as described above, and hydrating the anhydrous disodium salt.
  • the monohydrate of the disodium salt is formed. Since the anhydrous disodium salt is very hydroscopic, the hydrate forms upon exposure to atmospheric moisture.
  • the hydrating step is performed at from about ambient temperature to about 50° C., preferably ambient temperature to about 30° C. and in an environment having at least 50% relative humidity.
  • the anhydrous disodium salt may be hydrated with steam.
  • the preferred delivery agents may be selected from N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino) decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino) caprylic acid (SNAC) and their mono and di-salts, for example monosodium and disodium salts, ethanol solvates of their salts and the monohydrates of their salts and any combinations thereof, such as ethanol solvates of their sodium salts and the monohydrates of their sodium salts and any combinations thereof, for example.
  • Other salts, such as potassium, lithium and calcium are also contemplated.
  • a particularly surprising aspect of the present invention is the effect the chosen delivery agent may have on the dissolution time of the active ingredient.
  • the carrier is 5-CNAC
  • the transformation of an insoluble form, e.g. the solid form of sodium salt or free acid of 5-CNAC in a particular environment, for example the intestine environment, to a soluble form, e.g. the 5-CNAC in solution provides a mechanism whereby the active ingredient has a high dissolution rate, e.g. not more than ten minutes.
  • any insoluble form of a delivery agent which transforms into a soluble entity upon contact within the gastro intestinal environment (such as that of the duodenum environment, for example) may provide a mechanism for a high dissolution rate of an active ingredient.
  • the delivery agent such as 5-CNAC, for example or its salts, may provide a satisfactory, or optimum, microenvironment for the satisfactory, or optimum, rate of dissolution and/or absorption of a poly (amino acid) active ingredient.
  • the disodium salt of 5-CNAC may provide a satisfactory, or optimum, microenvironment for the absorption of salmon calcitonin.
  • the absorption of the salmon calcitonin may be measured by plasma concentration, for example.
  • the delivery agent is 5-CNAC.
  • the 5-CNAC may be in free or salt form and may consist of a wide range of particle sizes ranging from, for example, 50 to 5 ⁇ m average particle size.
  • the delivery agent is in micronized form.
  • the average particle size of the micronized delivery agent may be measured by milling coarse 5-CNAC and sampling periodically with reference particle size measurements to identify when the averaged desired particle size is achieved.
  • a process for micronising 5-CNAC is described in WO 2005/014031, which is incorporated herein by reference; see in particular page 10 and example 1, which describe the effects of different 5-CNAC size particles.
  • the delivery agent is preferably present in an amount of between 5 wt % and 80 wt %, particularly of between 10 wt % and 70 wt %, more particularly of between 20 wt % and 60 wt %, even more particularly of between 40 wt % and 60 wt % of the total mass of the pharmaceutical composition, for example 50 wt %.
  • the final pharmaceutical composition weight is 500 mg, this equates to amounts of 2.5 to 400 mg of the delivery agent present in the final pharmaceutical composition.
  • the delivery agent is 5-CNAC or salt thereof
  • its salt form is preferably present in amount of more than 90% weight per total weight of the 5-CNAC present in the composition, this particularly applies when the disodium salt of 5-CNAC is present.
  • the preferred delivery agent is the disodium salt of 5-CNAC.
  • the active ingredient to delivery agent ratio is preferably present between 1/25 to 1/400, particularly between 1/50 to 1/300, more particularly between 1/100 to 1/200, with the most preferred ratio in the case sCT/5-CNAC compositions being of 0.5 mg-1 mg sCT to 200 mg-300 mg of 5-CNAC disodium salt.
  • the disintegrant may be selected from any superdisintegrant, for example, synthetic polymers capable of swelling through absorption of water, of which crospovidones and povidones may be mentioned in particular. More specific examples of disintegrants are crospovidone, povidone, Explotab or AC-Di-Sol.
  • the disintegrant is Crospovidone.
  • Crospovidone is a synthetic crosslinked homopolymer of N-vinyl-2-pyrrolidone, also called 1-ethenyl-2-pyrrolidinone, having a molecular weight of 1,000,000 or more.
  • Superdisintegrants are agents that can absorb water and swell to a significant extent by either wicking effect or hydration. They are more efficient than conventional disintegrant due to their water uptake and swelling capacity.
  • agents may also be used that decrease disintegration time by effervescent and/or other means.
  • the disintegrant is preferably present in an amount from 0.02 wt % to 10 wt %, particularly from 0.2 wt % to 10 wt %, more particularly from 1.0 wt % to 8 wt %, e.g. 3 wt % to 7% of the total mass of the pharmaceutical composition, for example 5 wt %. Where the final pharmaceutical composition weight is 500 mg, this equates to amounts of the disintegrant between 0.1 mg to 50 mg.
  • crospovidones include Polyplasdone XL, Polyplasdone XL-10, Polyplasdonel NF-10 available from ISP, Kollidon CL, available from BASF Corporation.
  • the preferred crospovidone is Polyplasdone XL.
  • Povidone is a synthetic polymer consisting of linear 1-vinyl-2-pyrrolidinone groups having a molecular weight generally between 2,500 and 3,000,000.
  • Commercially available povidones include Kollidon K-30, Kollidon K-90F available from BASF Corporation and Plasdone K-30 and Plasdone K-29/32, available from ISP. Alternatively, they may be synthesized by known processes.
  • the diluent may be, for example Avicel PH 102 or 101.
  • the diluent may be present in the pharmaceutical composition of up to 90 wt % based on the whole composition, or may be used to make up any difference between the desired and actual final pharmaceutical composition mass, which may be, for example up to 600 mg, e.g. 500 mg.
  • the binder is present in an amount of between 20 and 70 wt % based on the whole composition, e.g. 40 to 60 wt %, e.g. 50 wt %. Where the final pharmaceutical composition weight is 500 mg, this equates to amounts of, for example, 100 mg to 350 mg.
  • the diluent is a microcrystalline cellulose.
  • the dissolution times of an active agent may be independent of the diluent.
  • a glidant or lubricant may increase dissolution rate of an active ingredient, this is known to the person in the field due to the hydrophobicity of the lubricant, i.e. magnesium stearate, sodium stearyl fumarate, calcium stearate etc.
  • disintegration and dissolution may be defined under USP sections ⁇ 701> and ⁇ 711>, which is incorporated herein by reference.
  • dissolution time the time is to be understood, which is required for a given amount (or fraction) of a drug to be released into solution from a solid dosage form. Dissolution time is measured in vitro, under conditions that simulate those that occur in vivo, in experiments in which the amount of drug in solution is determined as a function of time.
  • dissolution may be determined by the USP XXIII Paddle Method using a USP dissolution test apparatus 2 at 50 rpm.
  • DT disintegration time
  • the disintegration time is the time which is required for a tablet to break up into granules of specified size.
  • Factors such as the kind and amount of tablet binders and the degree of compression used in compacting the tablet ingredients are determinative of the disintegration time.
  • the disintegration time of the pharmaceutical composition according to the present invention is no more than 10 minutes, e.g. it may be not more than 9 minutes.
  • the disintegration time is up to 8 minutes, e.g. 6 minutes, for example it may be less than 8 minutes, as in the case of 7 minutes.
  • the DT is up to 5 minutes, e.g. between 1 and 4 minutes such as 2 minutes, for example.
  • the disintegration times are less than two minutes, e.g. 1 minute or less.
  • compositions have a dissolution time of up to ten minutes.
  • the disintegration times of the compositions of the present invention are any of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 minutes or any fraction thereof, such as for example 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 140, 150, 160, 170, 180 seconds etc.
  • Disintegration refers here to the physical process by which a tablet breaks down into fine particles, for example of less than 0.065 cm in diameter. This process is monitored visually and pertains to the physical integrity of the tablet alone. In a typical way, disintegration is performed by monitoring the time it takes for 100% of dispersed particles to pass through a coarse meshed cylinder, for example 7.75 cm log with an inside diameter of 21.5 mm and a wall approximately 2 mm thick in a water bath which is maintained at 37° C. ( ⁇ 2° C.), as per USP ⁇ 701>.
  • the disintegration time of a composition may be linked with the dissolution time.
  • the dissolution time is the time in which an active ingredient is dissolved into a liquid medium. Dissolution is monitored via UV or HPLC analysis and provides the approximate time required for full release of a drug.
  • a disintegrated composition such as, for example, a tablet are not necessarily found to be in solution and available for absorption.
  • a long disintegration time is incompatible with rapid drug absorption; a short disintegration time, by itself, does not ensure rapid absorption.
  • disintegration time corresponds to faster dissolution whereas longer disintegration time relates to slower dissolution. More specifically, a disintegration time of 6 min and below corresponds to dissolution of >90% at 20 minutes, a disintegration time of 9 mins corresponds to dissolution of ⁇ 30% at 20 minutes.
  • the dissolution time of the compositions has a linear relationship with the dispersion time of the compositions.
  • the disintegration time of the composition may be used to predict the dissolution time of the composition. Equally, where the dissolution time of the composition is known, the disintegration time of the composition may be calculated.
  • the disintegration time will be the disintegration time of the tablet in the stomach. Therefore, factors having an effect on the disintegration time of the tablet, e.g. tablet hardness, may also be used to predict the dissolution time of an active ingredient.
  • a successful dissolution parameter is one in which a therapeutically effective amount of the active substance, or substances, reaches the blood plasma.
  • a formulation containing 0.8 mg of calcitonin should provide a peak plasma concentration (C max ) of no less than 400 pg/mL and/or reduction in plasma calcium level of >20% in 6 hrs.
  • the rate and/or amount of absorption may be optimized and/or changed as required.
  • the bioavailability may be adjusted by adjusting the tablet hardness, for example.
  • the ingredients (excipients/carriers) of a tablet and the degree of compression in forming the tablet may influence the bioavailability of an active ingredient in a composition of the present invention.
  • the pharmaceutical composition is in the form of a compressed tablet.
  • the tablet preferably has a hardness of between 5 and 10 kilopascal.
  • the tablet hardness may be used to additionally determine the disintegration time of the pharmaceutical composition. It has been found by the present inventors that, using the same pharmaceutical composition, the tablet hardness has a linear relationship with disintegration time. Therefore, it is another aspect of the present invention that the disintegration time of the pharmaceutical composition, depends on the hardness of the tablet. More specifically, certain disintegration time can be achieved by controlling the hardness of the tablets compressed.
  • a tablet at preferred mass with preferred formulation that has a hardness between 5-20 Kp would typically has disintegration time of less than 6 mins.
  • the hardness of a tablet is directly related to the disintegration time of the tablet, as shown by Tables 1 and 2 below and FIGS. 3 and 4 .
  • the compression force applied to a particular composition when manufacturing a tablet may determine the disintegration time of the pharmaceutical composition.
  • the pharmaceutical composition additionally comprises a glidant agent and/or a stabiliser and/or a dry binder.
  • the pharmaceutical composition additionally comprises a glidant agent.
  • the glidant agent is, for example cab-o-sil.
  • the glidant agent may be present in an amount up to 1.5 wt %, e.g. 0.02 to 0.5 wt % based on the whole composition, e.g. 0.3 wt %. Where the final pharmaceutical composition weight is 500 mg, this equates to amounts of up to 7.5 mg.
  • the pharmaceutical composition additionally comprises a lubricant.
  • the lubricant is for example magnesium stearate.
  • the lubricant may be present in an amount of, for example 0.5 to 1.5 wt % based on the whole composition, e.g. 0.75 to 1.25 wt %, e.g. 1 wt %. Where the final pharmaceutical composition weight is 500 mg, this equates to amounts of 2.5 mg to 7.5 mg.
  • compositions of the present invention having the disintegration and/or dissolution properties as mentioned herein may also be combined with other technologies such as those described in WO 94/26778; U.S. Pat. No. 5,359,030; U.S. Pat. No. 5,438,040; U.S. Pat. No. 5,681,811; U.S. Pat. No. 6,191,105; U.S. Pat. No. 6,309,633; U.S. Pat. No. 6,380,405; U.S. Pat. No. 6,436,990; U.S. Pat. No. 6,458,776; WO 97/33531; U.S. Pat. No. 5,912,014; U.S. Pat. No. 608,618 and U.S. Pat. No. 6,479,692 (the content thereof is hereby incorporated by reference in its entirety).
  • the present invention includes methods for making the formulations and compositions described herein.
  • the present invention relates to a method for making a tablet having a disintegration-time of not more than 10 minutes, the method comprising:
  • the method can additionally comprise and of the following:
  • the compressing of the mixture into a tablet provides a tablet having a hardness of between 5 and 20 pa and such that the tablet has a disintegration time of not more than 10 minutes.
  • the formulation of the present invention may be used to treat a bone resorption disorder, such as osteoporosis, osteolyisis or Paget's disease, for example, or an arthritic condition, such as osteoarthritis, for example.
  • a method of preventing or/and treating a bone resorption disorder and/or an arthritic condition in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to the present invention, where the poly(amino acid) is calcitonin, e.g. salmon calcitonin in free form or salt form and the disintegration time of the pharmaceutical composition is up to 10 mins.
  • composition of the present invention may be used, when containing the required poly(amino acid), e.g. calcitonin, in the following:
  • a method of inhibiting resorption and normalizing turnover of sub-chondral bone in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to the present invention.
  • a method of preserving and stimulating cartilage via a direct or indirect effect on chondrocytes in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to the present invention.
  • a method of inhibiting phospholipase A2 and/or collagenase activity in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to the present invention. 4.
  • a method of obtaining stimulatory effect onglycosaminoglycan and/or proteoglycan synthesis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to the present invention. 5.
  • a method of acting on the inhomogeneity in density or stiffness of the subchondral bone in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to the present invention. 6.
  • a method of acting on the inflammatory process, leading to attenuations on pain in motion and related symptoms (e.g. circumference of knee, flexion angle of the knee, swelling stiffness) in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to the present invention.
  • a method to reduce the degenerative change in the joint in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition according to the present invention.
  • the pharmaceutical composition according to the present invention may be administered with, e.g. include, a second drug substance, where the said second drug substance is, for example a second bone resorption inhibitor, bone forming drug or pain reducing drug.
  • each substance may be independently administered simultaneously, separately or sequentially in relation to the composition of the present invention.
  • Suitable second drug substances may include a calcitonin of different origin, e.g. salmon, (Asul-7)-eel or human calcitonin, a calcitonin analogue or derivative thereof, a steroid hormone, e.g. an estrogen, a partial estrogen agonist or estrogen-gestagen combination, a SERM (Selective Estrogen Receptor Modulator) e.g. raloxifene, lasofoxifene, TSE-424, FC1271, Tibolone (Livial O), vitamin D or an analogue thereof or PTH, a PTH fragment or a PTH derivative e.g.
  • a calcitonin of different origin e.g. salmon, (Asul-7)-eel or human calcitonin, a calcitonin analogue or derivative thereof, a steroid hormone, e.g. an estrogen, a partial estrogen agonist or estrogen-gestagen combination, a SERM (S
  • lumiracoxib Prexige (E)
  • celecoxib Celebrex0
  • rofecoxib Vioxx (D)
  • valdecoxib BextraS
  • etoricoxib ArcoxiaG
  • mixed COX-1 and COX-2 inhibitors e.g. diclofenac.
  • a pharmaceutical combination comprising:
  • calcitonin e.g. salmon
  • (Asu1-7)-eel or human calcitonin in free form or salt form preferably in pharmaceutically acceptable oral delivery form, a delivery agent and a disintegrant, said pharmaceutical composition having a disintegration time of up to 10 minutes
  • a co-agent which is bone resorption inhibitor, bone forming drug or pain reducing agent, e.g. as disclosed above.
  • pharmaceutical combination means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, e.g. salmon calcitonin and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, e.g. salmon calcitonin and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the 2 compounds in the body of the patient.
  • the calcitonin e.g. salmon calcitonin in free form or in pharmaceutically acceptable salt form
  • a protease inhibitor e.g. cathepsin inhibitor, e.g. cathepsin K inhibitor.
  • kit of parts for use in the prevention and/or treatment of a bone resorption disorder and/or an arthritic condition, said kit comprising:
  • co-administration methods for each of the methods (i) to (vii) above, where the methods comprise the co-administration of a therapeutically effective amount of the pharmaceutical composition according to the present invention, e.g. a pharmaceutical composition containing calcitonin, e.g. salmon calcitonin in free form or salt form, in a pharmaceutical composition having a disintegration time of up to 10 minutes, and a second drug substance, said second drug substance being a bone resorption inhibitor, bone forming drug or pain reducing drug in free form or salt form.
  • a therapeutically effective amount of the pharmaceutical composition according to the present invention e.g. a pharmaceutical composition containing calcitonin, e.g. salmon calcitonin in free form or salt form, in a pharmaceutical composition having a disintegration time of up to 10 minutes, and a second drug substance, said second drug substance being a bone resorption inhibitor, bone forming drug or pain reducing drug in free form or salt form.
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • the appropriate dosage will, of course, vary depending upon, for example, the host and the nature and severity of the condition being treated. However, in general, satisfactory results will be obtained systemically at daily dosages of from about 0.5 ⁇ g/kg to about 10 ⁇ g/kg animal body weight, preferably 1 ⁇ g/kg to about 6 ⁇ g/kg body weight.
  • the pharmaceutical acceptable inactive excipients which are used in the pharmaceutical composition of calcitonin, e.g. in the oral pharmaceutical composition of calcitonin may include polymers and inactive compounds which for example, aid the pharmaceutical composition or manufacturing of the solid oral dosage form contemplated by the present invention or which may aid the release of the solid oral composition in the gastro-intestinal environment.
  • the disclosure provides provision of a particular dosage range for a calcitonin, particularly a calcitonin in free or salt form, e.g. salmon calcitonin, which is efficacious and well tolerated, i.e. safe for a patient to take.
  • a calcitonin particularly a calcitonin in free or salt form, e.g. salmon calcitonin, which is efficacious and well tolerated, i.e. safe for a patient to take.
  • compositions of the present invention may be used for the following:
  • a pharmaceutical composition comprising between 0.4 and 2.5 mg, preferably between 0.8 and 1.2 mg, most preferred about 1 mg of a calcitonin, e.g. salmon calcitonin.
  • Such oral delivery form is e.g. a pharmaceutical composition for oral delivery of salmon calcitonin comprising:
  • composition a therapeutically effective amount of said salmon calcitonin (B) at least one absorption enhancer effective to promote bioavailability of said salmon calcitonin said composition having a disintegration time of up to 10 mins.
  • enhances examples include 5-CNAC, SNAC and fatty acids such as Na Caprate, Na Capralate.
  • compositions with which the usefulness of calcitonin in the treatment of osteoarthritis is shown may be provided as a capsule including a soft-gel capsule, tablet, caplet, suppository or other solid oral dosage form, all of which can be prepared by methods well known in the art, provided that the composition has a disintegration time of up to 10 minutes.
  • the compositions have a disintegration time of up to 10 minutes. Or if tested in appropriate condition, it has more than 90% of content dissolved in 20 minutes.
  • the solid pharmaceutical compositions may be prepared by first grinding either the delivery agent or the delivery agent with any combination of the additional ingredients of the present composition to a micronized particle size.
  • the micronized delivery agent or micronized delivery agent plus micronized additional ingredients of the present invention may then be further processed by conventional methods e.g. by blending a mixture of the active agent or active agents, the delivery agent, the crospovidone or povidone and/or other ingredients, kneading, and filling into capsules or, instead of filling into capsules, molding followed by further tableting or compression-molding to give tablets.
  • a solid dispersion may be formed by known methods followed by further processing to form a tablet or capsule.
  • Salmon calcitonin, 5-CNAC and crospovidone were blended together in a first blending step.
  • Avicel PH 102 was screened and added to the mixture and blended in a second blending step.
  • Magnesium stearate was then added and the mixture was blended further in a final blending step.
  • the final blend was compressed into a 500 mg tablet and evaluated in a Rhesus monkey. The results are shown in FIG. 5 .
  • composition comprising:
  • Example 2 Salmon calcitonin and Avicel PH 102 were blended in a first blending step. 5-CNAC and crospovidone were then added to the first blend in a second blending step. Finally, Magnesium Stearate was added in a final blending step.
  • the final blend was then compressed at 3 different compression levels to obtain 3 different batches of tablets each having a different hardness, in order to provide 3 different disintegration times:
  • Example 2 A similar blend was made to that of Example 1, except that an amount of Cab-o-sil was added to form a composition comprising:
  • Salmon calcitonin, 5-CNAC and crospovidone were blended in a first blending step.
  • Avicel and Cab-o-sil were screened and added in a second blending step.
  • Magnesium stearate was added in a final blending step.
  • the final blend was compressed into a 500 mg tablet. The incorporation of Cab-o-sil improved the compression profile of the tablet.
  • composition was made as described in Example 3, except that the composition comprised:
  • Unit weight (a+b) of Avicel PH 101 (I) and (II) corresponds to combined weight of Avicel PH 101.
  • Unit weight (a+b) of Avicel PH 101 (I) and (II) corresponds to combined weight of Avicel PH 101.
  • Batch A 1. 0.8 mg, DT 2 m35 s, Force 8.5 kN 2. 0.8 mg, DT 5 m40 s, Force 11.2 kN 3. 0.8 mg, DT 8 m34 s, Force 12.1 kN Batch B 1. 0.6 mg, DT 3 m40 s-5 m35 s, Force 8 kN 2. 0.6 mg, DT 6 m15 s-7 m55 s, Force 9 kN 3. 0.6 mg, DT 9 m, Force 10.2 kN Batch C 1. 0.8 mg, DT 2 m Force 8.3 kN
  • the Rhesus monkeys fast overnight prior to dosing and are restrained in chairs fully conscious, for the duration of the study period.
  • One tablet each Batch is administered to each monkey via a gavage tube followed by 10 mL of water.
  • Rhesus monkey blood samples are collected immediately before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, and 6 hours after administration.
  • Resulting plasma salmon calcitonin for each dose and for each monkey is determined by radio-immunoassay.
  • the primate plasma salmon calcitonin (SCt) for one batch and one time period, mean plasma SCt concentrations for all monkeys for one batch and one time period, Standard Deviation (SD) of plasma SCt concentrations for one batch and one time period, and Standard Error of the Mean (SEM) for plasma SCt concentrations for all monkeys for one batch and one time period are calculated and reported in FIG. 5 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US12/093,383 2005-11-17 2006-11-16 Pharmaceutical Composition Abandoned US20080255048A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/093,383 US20080255048A1 (en) 2005-11-17 2006-11-16 Pharmaceutical Composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73763105P 2005-11-17 2005-11-17
US12/093,383 US20080255048A1 (en) 2005-11-17 2006-11-16 Pharmaceutical Composition
PCT/US2006/044642 WO2007061829A2 (en) 2005-11-17 2006-11-16 Pharmaceutical composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044642 A-371-Of-International WO2007061829A2 (en) 2005-11-17 2006-11-16 Pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/079,400 Division US20110218148A1 (en) 2005-11-17 2011-04-04 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
US20080255048A1 true US20080255048A1 (en) 2008-10-16

Family

ID=37875983

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/093,383 Abandoned US20080255048A1 (en) 2005-11-17 2006-11-16 Pharmaceutical Composition
US13/079,400 Abandoned US20110218148A1 (en) 2005-11-17 2011-04-04 Pharmaceutical composition
US14/718,595 Expired - Fee Related US9622975B2 (en) 2005-11-17 2015-05-21 Pharmaceutical composition

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/079,400 Abandoned US20110218148A1 (en) 2005-11-17 2011-04-04 Pharmaceutical composition
US14/718,595 Expired - Fee Related US9622975B2 (en) 2005-11-17 2015-05-21 Pharmaceutical composition

Country Status (10)

Country Link
US (3) US20080255048A1 (enrdf_load_stackoverflow)
EP (1) EP1951207A2 (enrdf_load_stackoverflow)
JP (3) JP2009515993A (enrdf_load_stackoverflow)
KR (2) KR101432313B1 (enrdf_load_stackoverflow)
CN (1) CN101309674A (enrdf_load_stackoverflow)
AU (1) AU2006318815B2 (enrdf_load_stackoverflow)
BR (1) BRPI0618723A2 (enrdf_load_stackoverflow)
CA (1) CA2626933C (enrdf_load_stackoverflow)
RU (1) RU2469709C2 (enrdf_load_stackoverflow)
WO (1) WO2007061829A2 (enrdf_load_stackoverflow)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US11413296B2 (en) 2005-11-12 2022-08-16 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP3542790B1 (en) 2012-03-22 2023-09-13 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618723A2 (pt) * 2005-11-17 2011-09-06 Novartis Ag composição farmacêutica oral na forma de um comprimido prensado
WO2012080471A1 (en) 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN103619175B (zh) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
EP2991671B1 (en) 2013-05-02 2018-08-15 Novo Nordisk A/S Oral dosing of glp-1 compounds
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
EP3256114A4 (en) 2015-02-09 2018-11-21 Entera Bio Ltd. Treatment of osteoporosis
WO2018033927A1 (en) 2016-08-17 2018-02-22 Entera Bio Ltd. Formulations for oral administration of active agents
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159345A (en) * 1977-04-13 1979-06-26 Fmc Corporation Novel excipient and pharmaceutical composition containing the same
US4755385A (en) * 1985-07-10 1988-07-05 Dr. Karl Thomae, Gmbh Oral pharmaceutical preparations containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5213806A (en) * 1990-11-29 1993-05-25 Hokuriku Pharmaceutical Co., Ltd. Pharmaceutical composition comprising calcium polycarbophil
US5948422A (en) * 1995-02-08 1999-09-07 Yamanouchi Europe B.V. Oral dosage-forms containing a β-lactam antibiotic
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US20020123459A1 (en) * 2000-12-06 2002-09-05 Ault Joseph M. Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20050186267A1 (en) * 2002-09-13 2005-08-25 Thompson Diane O. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773A (en) 1848-09-19 Sizing and drying cotton-batting
US608618A (en) 1898-08-09 Thomas millen
US536A (en) 1837-12-26 Beady binder for binding newspapers
US5866A (en) 1848-10-17 Dentist s deill
US647A (en) 1838-03-21 Improved fishing-seine for deep water
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
IL154537A0 (en) 2000-08-29 2003-09-17 Nobex Corp 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
JP5073153B2 (ja) * 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
AU2004262906B2 (en) * 2003-07-23 2008-04-03 Nordic Bioscience A/S Use of calcitonin in osteoarthritis
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
BRPI0618723A2 (pt) * 2005-11-17 2011-09-06 Novartis Ag composição farmacêutica oral na forma de um comprimido prensado

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159345A (en) * 1977-04-13 1979-06-26 Fmc Corporation Novel excipient and pharmaceutical composition containing the same
US4755385A (en) * 1985-07-10 1988-07-05 Dr. Karl Thomae, Gmbh Oral pharmaceutical preparations containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5213806A (en) * 1990-11-29 1993-05-25 Hokuriku Pharmaceutical Co., Ltd. Pharmaceutical composition comprising calcium polycarbophil
US5948422A (en) * 1995-02-08 1999-09-07 Yamanouchi Europe B.V. Oral dosage-forms containing a β-lactam antibiotic
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US20020123459A1 (en) * 2000-12-06 2002-09-05 Ault Joseph M. Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20050186267A1 (en) * 2002-09-13 2005-08-25 Thompson Diane O. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11413296B2 (en) 2005-11-12 2022-08-16 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP3542790B1 (en) 2012-03-22 2023-09-13 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof

Also Published As

Publication number Publication date
JP6049317B2 (ja) 2016-12-21
WO2007061829A2 (en) 2007-05-31
KR20140053419A (ko) 2014-05-07
US20150250729A1 (en) 2015-09-10
EP1951207A2 (en) 2008-08-06
KR20080066958A (ko) 2008-07-17
AU2006318815A1 (en) 2007-05-31
JP2009515993A (ja) 2009-04-16
JP2015145410A (ja) 2015-08-13
RU2008123380A (ru) 2009-12-27
WO2007061829A3 (en) 2007-08-30
BRPI0618723A2 (pt) 2011-09-06
RU2469709C2 (ru) 2012-12-20
US20110218148A1 (en) 2011-09-08
CN101309674A (zh) 2008-11-19
US9622975B2 (en) 2017-04-18
CA2626933C (en) 2015-12-29
JP2012211159A (ja) 2012-11-01
CA2626933A1 (en) 2007-05-31
JP6147290B2 (ja) 2017-06-14
KR101432313B1 (ko) 2014-08-20
AU2006318815B2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
US9622975B2 (en) Pharmaceutical composition
US8765675B2 (en) Use of calcitonin in osteoarthritis
US9272040B2 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments
US20150283212A1 (en) Oral calcitonin compositions and applications thereof
MX2008006319A (en) Pharmaceutical composition
HK1152229B (en) Use of calcitonin in osteoarthritis
HK1089935B (en) Use of calcitonin in osteoarthritis

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION